US medical company Liminatus Pharma plans to raise and deploy $500 million to invest in BNB.

On July 28, according to a report by businessinsider, the clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) announced today that it plans to strategically expand into the Crypto Assets and Blockchain fields. The company intends to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management program. Through this platform, Liminatus plans to raise and deploy up to $500 million in a phased manner, with the goal of making strategic long-term investments in BNB. Liminatus emphasizes that while the company remains fully committed to its core business—advancing cancer treatment and pancreatic cancer diagnostic technologies—it believes that expanding into the digital asset space is a necessary measure to support long-term growth and enhance shareholder value. Liminatus is a clinical-stage biopharmaceutical company dedicated to developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.